Women using GLP-1 receptor agonist medications like semaglutide and tirzepatide are reporting a range of health improvements that extend far beyond appetite suppression and weight loss. As prescriptions for these drugs soar, clinical evidence and patient experiences are revealing that GLP-1 drugs may offer protective effects against heart disease, liver disease, certain cancers, and even fertility challenges. These discoveries are reshaping how doctors think about the broader role these medications might play in women's health.

What Health Benefits Are Women Actually Experiencing on GLP-1 Drugs?

Jennifer Kirtley of Lake Worth, Florida, lost 180 pounds on Wegovy over two years, but the changes she noticed went well beyond the number on the scale. "My blood pressure is down. My A1C is down. I have no desire to drink alcohol, and my food cravings have gone away," Kirtley said. She also experienced unexpected relief from arthritis inflammation in her knee, a benefit she attributes to the anti-inflammatory effects of GLP-1 medications.

Kirtley's experience reflects a pattern emerging across clinical practice and research. Beyond the gastrointestinal side effects that dominate early conversations about these drugs, patients and doctors are documenting improvements in conditions that seem unrelated to weight loss at first glance. The mechanisms behind these benefits vary, but many appear connected to how GLP-1 drugs reduce chronic inflammation throughout the body.

The documented health improvements women are reporting include:

• Cardiovascular Protection: A 2023 study published in the New England Journal of Medicine involving more than 17,000 patients found that semaglutide reduced the risk of major cardiovascular events, including heart attack, stroke, and cardiovascular death, by approximately 20% in overweight or obese adults who already had cardiovascular disease.
• Liver Disease Improvement: South Florida obesity doctors report seeing improvement in nonalcoholic fatty liver disease in patients taking semaglutide. The FDA approved Wegovy to treat metabolic-associated steatohepatitis (MASH), a severe form of metabolic liver disease, with about 6% of U.S. adults, or roughly 14.9 million people, having MASH.
• Cancer Risk Reduction: A 2025 study by University of Florida researchers found that GLP-1 medications are associated with a 17% lower risk of developing 14 obesity-associated cancers, including endometrial, meningioma, and ovarian cancers.
• Fertility and Reproductive Health: Women with polycystic ovary syndrome (PCOS), a common hormone imbalance affecting 30% to 35% of those seeking fertility treatment, have reported improved ovulation and easier symptom management after weight loss on GLP-1 drugs.

How Are GLP-1 Drugs Improving Women's Fertility and PCOS Symptoms?

One of the most striking trends emerging from patient reports involves fertility improvements, particularly among women with PCOS. Social media has been filled with stories of "Ozempic babies," women who conceived after struggling with infertility while taking semaglutide or other GLP-1 medications. While these anecdotal reports initially seemed surprising, fertility specialists are beginning to understand the mechanism.

"Weight loss can enhance ovulation and ease symptoms of polycystic ovary syndrome, a common hormone imbalance," explained Dr. Armando Hernandez-Rey, a South Florida fertility specialist.

Dr. Armando Hernandez-Rey, Fertility Specialist

The connection appears straightforward: GLP-1 drugs suppress appetite and promote weight loss, and weight loss itself improves hormonal balance in women with PCOS. However, Hernandez-Rey emphasizes an important caution. "It is strongly recommended to stop GLP-1 medications at least one to two months before attempting pregnancy to avoid potential risks to a fetus," he stated. Yet many women have conceived while still taking these medications, and Hernandez-Rey noted he has not observed negative effects on babies born after maternal GLP-1 exposure.

Limited data currently exists on exactly how GLP-1 medications affect fertility, pregnancy, and breastfeeding. However, as the popularity of these drugs grows, so does the research. As many as a dozen studies involving GLP-1 use are underway specifically for women with PCOS and obesity.

Can GLP-1 Drugs Help Prevent Endometrial Cancer and Precancerous Conditions?

One of the most promising findings for women involves the potential to prevent or reverse precancerous changes in the uterine lining. Dr. Jacob Tangir, with The Center for Gynecologic Oncology in Miramar, explained that GLP-1 drugs are showing effectiveness against complex atypical hyperplasia, a precancerous condition in the uterine lining.

"GLPs together with progesterone reverse this pre-cancer condition in a higher proportion of people than if they were treated with progesterone alone. And that's a big thing for younger patients who are overweight because it will help them preserve the uterus so they can conceive," said Dr. Jacob Tangir.

Dr. Jacob Tangir, The Center for Gynecologic Oncology

The broader cancer protection appears to stem from weight loss and inflammation reduction rather than direct drug action on cancer cells. Dr. Sonya Daryanani, an internist and obesity specialist with Nova Southeastern University, explained the mechanism: "The bottom line is that, in the big picture, it comes down to decreasing the inflammatory effect. You are decreasing the chronic inflammation, and that can really help in reducing tumors".

How to Monitor for Side Effects While Taking GLP-1 Medications

While the emerging benefits are encouraging, GLP-1 drugs do carry side effects and safety considerations that women should understand before starting treatment.

• Common Gastrointestinal Effects: Nausea, vomiting, diarrhea, and constipation are the most frequently reported side effects across the GLP-1 class. These typically occur early in treatment and often improve as the body adjusts to the medication.
• Hair Thinning and Skin Changes: Some women, including Jennifer Kirtley, have reported hair thinning and excess skin as side effects. These appear to be related to rapid weight loss rather than the medication itself.
• Thyroid Concerns: Both semaglutide and tirzepatide carry a boxed warning for thyroid C-cell tumors based on rodent studies, though human evidence of this risk remains limited.
• Emerging Safety Signals: Retatrutide, an investigational triple-agonist drug still in clinical trials, has shown a dysesthesia signal (abnormal skin sensations like tingling or burning) in up to 21% of participants on the highest dose, compared to 0.7% on placebo. This side effect has not been reported at significant rates with semaglutide or tirzepatide.

What's the Difference Between Currently Available GLP-1 Drugs and Experimental Options?

The GLP-1 medication landscape includes drugs at different stages of development and approval. Semaglutide, the active ingredient in Wegovy and Ozempic, is a single agonist that activates GLP-1 receptors only. Tirzepatide, the active ingredient in Mounjaro and Zepbound, is a dual agonist that activates both GLP-1 and GIP receptors. Both are FDA-approved and widely available.

Retatrutide, sometimes called "GLP-3" in social media discussions, is an investigational triple-agonist drug from Eli Lilly that activates GLP-1, GIP, and glucagon receptors. Phase 3 trial data from the TRIUMPH program showed approximately 28.7% mean body-weight loss over 68 weeks on the 12 mg dose, among the largest average reductions reported in any Phase 3 obesity trial to date. However, retatrutide is not FDA-approved, is not legally available for prescription, and is not eligible for compounding under current FDA regulations. The earliest realistic approval window is 2027, contingent on the rest of the Phase 3 readouts.

Importantly, online vendors selling "retatrutide peptide" or "GLP-3" vials marketed as "research use only" are operating outside the regulatory framework. The FDA has issued explicit warnings about these products, noting that purity, dosage accuracy, and sterility are unverified.

What Do Experts Say About Long-Term GLP-1 Use for Women?

As more women adopt GLP-1 medications for weight management and metabolic health, questions about long-term use are becoming more common. Jennifer Kirtley, who has lost 180 pounds on Wegovy, expressed her intention to continue indefinitely. "I intend to stay on it forever," she said, noting that she is transitioning to the newly available Wegovy pill formulation.

This reflects a broader shift in how doctors and patients view these medications. Rather than short-term weight-loss tools, GLP-1 drugs are increasingly being considered as chronic disease management medications, similar to how blood pressure or cholesterol medications are used long-term. The cardiovascular benefits documented in large trials, combined with emerging evidence of protection against liver disease and certain cancers, suggest that for many women, particularly those with existing cardiovascular disease or metabolic conditions, the benefits of long-term use may outweigh the risks.

However, the research landscape remains dynamic. Additional studies are underway examining GLP-1 use in women with PCOS, potential effects on Alzheimer's disease, and associations with reduced addiction risk. As these findings emerge, clinical guidance will likely continue to evolve, offering women and their doctors more detailed information to make informed decisions about whether GLP-1 medications are appropriate for their individual health situations.